Jan Z.
- Country
- Poland
- Department
- Klinika Hematologii i Transplantologii
Research Overview
- Evaluation of Autologous CAR T Cells (Tarcidomgen Kimleucel) in Refractory and Relapsed CD19+ B Cell Neoplasms
- Phase 1 Study of JNJ-80948543, a T-cell Redirecting Antibody, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients
- Efficacy and Safety Evaluation of Glofitamab with Gemcitabine and Oxaliplatin Versus Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Data & Insights
Has run more than one trial at 175 of 313 partner sites.
Specializations
Lymphoma Research
Specialized in investigating innovative treatments for various forms of B-cell lymphomas, including approaches for both newly diagnosed and relapsed/refractory cases. The investigator has particular expertise in diffuse large B-cell lymphoma and follicular lymphoma.
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- B-cell Lymphoma Therapeutics
Focuses on evaluating novel immunotherapy approaches and targeted treatments for lymphoid malignancies.
Leukemia Studies
Conducts research in chronic lymphocytic leukemia treatment modalities, with emphasis on investigating new therapeutic agents and combination approaches.
- CLL/SLL Treatment Strategies
- Myelodysplastic Syndrome
- Novel Drug Combinations
Explores innovative therapeutic approaches including targeted therapies and immunological interventions.
Multiple Myeloma Research
Investigates cutting-edge treatments for multiple myeloma, including cell therapy approaches and novel drug combinations. Particular focus on post-transplant therapeutic strategies and treatment of newly diagnosed cases.
- CAR T-cell Therapy
- Maintenance Therapy
- Novel Therapeutic Combinations
Specializes in developing treatment strategies for various stages of multiple myeloma progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.